Topiramate Tablet
Product Images NDC 43063-735

4 FDA label images from Pd-rx Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 43063-735). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

43063735 Label (43063735)

43063735 Label (43063735)
Topiramate USP 25 mg tablet label showing a prescription medication with 60 tablets per container. The label includes the NDC number 43063-735-60 and is manufactured by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. The label features dosage instructions placeholders, reorder and lot numbers, expiration date 04/2021, and a warning to keep out of reach of children.*
FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01
Chemical structure of Topiramate, the active ingredient, showing its molecular formula with functional groups including a sulfamate and multiple oxygen-containing rings.*
FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02
A cumulative rate graph depicting time to first seizure for Topiramate at 50 mg/day and 400 mg/day dosages in patients. The x-axis represents time in days up to 500 days, and the y-axis shows cumulative seizure rates, with separate curves for each dosage group and a reported p-value of 0.0002 illustrating statistical comparison.*
FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03
A bar chart depicting the change from baseline to double-blind phase in average weekly migraine periods in two studies. The chart compares Placebo, Topamax 50 mg/day, 100 mg/day, and 200 mg/day doses, showing bars for Study 10 and Study 11 with statistical significance indicated for the 100 mg/day and 200 mg/day Topamax doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.